But unlike the many, more common antiviral drugs that can be used to fight against viruses such as flus, protease inhibitors can also be used to help combat HIV (human immunodeficiency virus).

With the introduction of HIV protease inhibitors (PIs) in 1995, it was found that major and prolonged reductions in viral burden could be achieved by the combination of a PI with two NRTIs ...

and isolates from individuals who have received at least three protease inhibitors. Figure 1: One analysis returned by HIV-SEQ. For RT isolates, the categories include subtype B RT isolates from ...

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

These protease inhibitors, despite their side effects and ... but at a portal through which HIV enters white blood cells and attacks the immune system. Scientists in 1996 identified the portal ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Australia: A recent study published in Clinical Infectious Diseases has shown that the current use of integrase strand ...

Food indeed contributes to the pharmacokinetic variability of protease inhibitors (PIs). [1] The exact mechanism(s) are poorly understood. As determined by measuring the area under the ...

Drugs to treat HIV and AIDS could be effective at stopping ... Its research found that retroviral protease inhibitors ritonavir, atazanavir and lopinavir "reduced proliferation of schwannoma ...

What to avoid with this at-home COVID-19 treatment Paxlovid is a combination antiviral medication that contains nirmatrelvir (a protease inhibitor) and ritonavir (originally used to treat HIV ...